Nobuichi Kuribayashi
Overview
Explore the profile of Nobuichi Kuribayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Honda M, Sugawara M, Kuribayashi N, Aiso Y, Ito S, Ito K, et al.
J Diabetes Investig
. 2025 Mar;
PMID: 40022489
Aims/introduction: As the prevalence of diabetes increases with age, the number of elderly patients with diabetes in Japan, a super-aged society, continues to increase. We conducted a survey to investigate...
2.
Uchida D, Sato Y, Kanatsuka A, Kuribayashi N, Nakamura S, Ko S, et al.
Diabetol Int
. 2025 Jan;
16(1):153-161.
PMID: 39877444
Objectives: This clinical study assessed the three-year, long-term effects of esaxerenone, a non-steroidal aldosterone receptor blocker, on Japanese patients with type 2 diabetes, diabetic kidney disease, and hypertension who were...
3.
Yoneda C, Kobayashi J, Kuribayashi N
Diabetol Int
. 2024 Aug;
15(3):569-576.
PMID: 39101186
Background: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are the most widely used oral hypoglycemic drugs in Japan. However, once-daily oral semaglutide has been reported to reduce glycated hemoglobin (HbA1c) and body weight...
4.
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, et al.
Sci Rep
. 2023 Sep;
13(1):14649.
PMID: 37669959
We previously reported in the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A) that alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, attenuated the progression of carotid atherosclerosis in subjects...
5.
Tamura Y, Kaga H, Abe Y, Yoshii H, Seino H, Hiyoshi T, et al.
Nutrients
. 2023 Jul;
15(13).
PMID: 37447194
Sarcopenia is a geriatric syndrome characterized by decreased physical performance, muscle mass, and strength. Since the intake of 5-aminolevulinic acid (ALA) with iron can increase muscle mass and mitochondria in...
6.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al.
Cardiovasc Diabetol
. 2023 Jun;
22(1):143.
PMID: 37349722
Background: This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes...
7.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al.
Diabetes Ther
. 2021 Aug;
12(9):2499-2515.
PMID: 34357559
Introduction: Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese...
8.
Watanabe Y, Suzuki D, Kuribayashi N, Uchida D, Kato M, Ohashi H, et al.
Sci Rep
. 2021 Jun;
11(1):11350.
PMID: 34059720
Sodium-glucose cotranspsorter-2 (SGLT2) inhibitors (SGLT2i) involve loss of skeletal muscle mass, potentially leading to inadequate HbA1c reduction in type 2 diabetes (T2DM), since muscle mass is related to insulin sensitivity....
9.
Wakasugi S, Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, et al.
Cardiovasc Diabetol
. 2021 Jan;
20(1):15.
PMID: 33413339
Background: Previous studies have suggested that high mean glucose levels and glycemic abnormalities such as glucose fluctuation and hypoglycemia accelerate the progression of atherosclerosis in patients with type 2 diabetes....
10.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al.
Cardiovasc Diabetol
. 2021 Jan;
20(1):4.
PMID: 33397376
Background: Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP)....